Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 16/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3088130 | 0.88 | HTT (0.57) | ADORA2AADORA1HTTCYP3A4LMNA | |
| SCHEMBL3079128 | 0.87 | ADORA2A (0.59) | ADORA2AADORA1HTTCYP3A4ALDH1A1 | |
| SCHEMBL2814529 | 0.84 | ADORA2A (0.65) | ADORA2AADORA1HTTCYP3A4 | |
| SCHEMBL3087723 | 0.81 | ALDH1A1 (0.59) | ADORA2AADORA1HTTCYP3A4ALDH1A1 | |
| SCHEMBL3085450 | 0.79 | ADORA2A (0.68) | ADORA2AADORA1CYP3A4ALDH1A1 | |
| SCHEMBL3077398 | 0.78 | ADORA2A (0.64) | ADORA2AADORA1ALDH1A1 | |
| SCHEMBL19690843 | 0.78 | HTT (0.53) | ADORA2AADORA1HTTCYP3A4LMNA | |
| SCHEMBL3093468 | 0.74 | ADORA2A (0.50) | ADORA2AADORA1GAATP53ALDH1A1 | |
| SCHEMBL1936057 | 0.73 | HTT (0.86) | HTTCYP3A4LMNATP53 | |
| SCHEMBL3092078 | 0.72 | HTT (0.63) | HTTLMNATP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234341-A1 | SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2010-09-16 | — | — | US | disclosed |
| US-20100234341-A1 | SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2010-09-16 | — | — | US | disclosed |
| US-20100234341-A1 | SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234341-A1 | SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA3, ADORA1, ADORA2A | ADORA2A 3/4885ADORA1 2/4885HTT 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.